Possible Shift in Medicare Drug Organization May Give Pharma Heartburn

A possible reshaping of how some Medicare drugs are paid for has drug companies feeling sick. Health and Human Services Secretary Alex Azar's plan to consolidate at least some Part B prescription drugs under Part D could cost pharmaceutical companies real money since while there are no price negotiations under Part B, Part D includes discount, rebates and negotiating tools.